Navigation Links
Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
Date:3/20/2008

NEW YORK, March 20 /PRNewswire/ -- Dreier LLP (http://www.dreierllp.com) announces that a class action lawsuit was commenced in the U.S. District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") (Nasdaq: VRTX) publicly traded securities during the period from June 12, 2007 through November 2, 2007, inclusive (the "Class Period"). The Complaint alleges that Vertex and certain of the Company's officers and directors (collectively, the "Defendants") violated the Securities Exchange Act of 1934.

If you purchased Vertex publicly traded securities during the Class Period, you may be a member of the proposed Class. You must move the Court on or before May 12, 2008 if you wish to serve as a lead plaintiff. Lead plaintiffs must meet certain legal requirements. If you purchased Vertex publicly traded securities and want to discuss your legal rights, you may contact Bruce D. Bernstein (classlaw@dreierllp.com) of Dreier LLP at 800-952- 8897. Class members may retain counsel of their choice and move the Court to serve as a lead plaintiff, or may choose to do nothing and remain absent class members.

Vertex is a pharmaceutical company engaged in the discovery, development and commercialization of small molecule drugs for the treatment of serious diseases.

The Complaint alleges that, among other things, during the Class Period Defendants misled investors by making materially false and misleading statements concerning the development of Vertex's new HCV protease inhibitor: telaprevir or VX-950. Ultimately, Vertex intends to use the inhibitor in a new drug targeted at the treatment of hepatitis C. Among other things, the Complaint alleges that Defendants made positive statements concerning VX-950 and the Company's PROVE 2 trial while simultaneously failing to disclose unfavorable data uncovered during the PROVE 2 trial. On November 2, 2007, before the market closed, the Company disclosed the truth concerning the PROVE 2 trial. As a direct and proximate result of this news, the price of Vertex stock declined $2.74 per share to close at $28.90 per share, a one day decline of 9%, on extremely high trading volume.

Dreier LLP's Class Action Litigation Group has vast experience representing domestic and foreign institutional and individual investors in securities and other class actions throughout the country. The partners who head Dreier LLP's Class Action Litigation Group have successfully prosecuted securities fraud class actions in a wide variety of industries and have played a significant role in cases that have resulted in some of the largest securities class action settlements. Prior results do not guarantee a similar outcome. As of the date of this Notice, Dreier LLP has not filed a Complaint against Vertex.

Background on Dreier LLP

Dreier LLP was founded in 1996 by Marc Dreier as a more responsive and innovative alternative to traditional "large-firm" lawyering. Dreier LLP represents a wide range of institutional, entrepreneurial and individual clients in diverse sectors of financial, industrial and service-oriented markets. The firm's principal practices are commercial litigation, class action litigation, real estate, bankruptcy and corporate reorganization, employment, corporate and securities, entertainment, intellectual property, matrimonial and tax. Dreier LLP's Los Angeles affiliate, Dreier Stein Kahan Browne Woods George LLP, has its principal practice in entertainment and commercial litigation and corporate transactions. The firm's New York affiliate Schlesinger Gannon & Lazetera LLP has an extensive practice in the area of trusts and estates law. Pitta & Dreier LLP is an affiliate which specializes in labor law, and Pitta, Bishop, Del Giorno & Dreier LLP specializes in government relations. In the 12 years since its founding, Dreier LLP, with its affiliate members, has grown to more than 200 attorneys, with its principal office at 499 Park Avenue in Manhattan, and additional offices in Los Angeles and Santa Monica, California; Albany, New York; and Stamford, Connecticut.

Attorney advertising


'/>"/>
SOURCE Dreier LLP
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Blue Cross and Blue Shield of Illinois Announces Wellness Tools and Resources
2. Blue Cross and Blue Shield of Illinois Announces Campaign to Address Childhood Obesity
3. Blue Cross and Blue Shield of Illinois Announces 2007 Charitable Donations
4. IPC The Hospitalist Company Announces Board of Director Member Changes
5. MedCom Announces Court Rules Card Activation Technologies Patent Is Valid
6. Patrick G. Ryan Announces Intention to Retire from Aon
7. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
8. Takeda Announces New U.S. Leadership
9. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
10. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
11. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time ... already been receiving positive feedback from customers trying the product for the first time, ... Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at ...
(Date:9/20/2017)... ... ... The Centers for Medicare and Medicaid Services (CMS) stated in the Inpatient ... Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments over the next ... on October 17, 2017 at 2 P.M. EST and uncover how you can prepare ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... feel good program from Leany Greeny delivers positive results in just three weeks. ... health and kickstart the metabolism. Fitting seamlessly into hectic work and family schedules, ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting ... an average life. This mouse sets out on a journey that will show that ... is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Psalms of ... give peace of mind and move the readers one step closer to God. “Psalms ... has realized that his mistakes that have been made within his life are the ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
Breaking Medicine Technology: